These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

792 related items for PubMed ID: 14519633

  • 1. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH.
    Clin Cancer Res; 2003 Sep 15; 9(11):4108-15. PubMed ID: 14519633
    [Abstract] [Full Text] [Related]

  • 2. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA.
    Clin Cancer Res; 1997 Jul 15; 3(7):1117-23. PubMed ID: 9815791
    [Abstract] [Full Text] [Related]

  • 3. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
    Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ.
    Clin Cancer Res; 2001 Dec 15; 7(12):3912-9. PubMed ID: 11751482
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G.
    Clin Cancer Res; 2008 Mar 01; 14(5):1464-9. PubMed ID: 18316570
    [Abstract] [Full Text] [Related]

  • 6. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ, Millenson M, O'Dwyer P, Kosierowski R, Alexander R, Litwin S, McAleer CA, Bonjo CA, Ozols R.
    Semin Oncol; 1996 Dec 01; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial.
    Greco FA, Hainsworth JD.
    Semin Oncol; 1997 Aug 01; 24(4 Suppl 12):S12-14-S12-17. PubMed ID: 9331113
    [Abstract] [Full Text] [Related]

  • 11. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ.
    J Clin Oncol; 2008 Jan 20; 26(3):468-73. PubMed ID: 18202422
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
    Okamoto I, Moriyama E, Fujii S, Kishi H, Nomura M, Goto E, Kiyofuji C, Imamura F, Mori T, Matsumoto M.
    Jpn J Clin Oncol; 2005 Apr 20; 35(4):188-94. PubMed ID: 15845567
    [Abstract] [Full Text] [Related]

  • 13. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
    Ichiki M, Kawasaki M, Takayama K, Ninomiya K, Kuba M, Iwami F, Miyazaki N, Oishi K, Takeo S, Aizawa H, Nakanishi Y.
    Cancer Chemother Pharmacol; 2006 Sep 20; 58(3):368-73. PubMed ID: 16395589
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH, Paul DM, Hande KR, DeVore R.
    Semin Oncol; 1996 Dec 20; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Goffin JR, Anderson IC, Supko JG, Eder JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT.
    Clin Cancer Res; 2005 May 01; 11(9):3417-24. PubMed ID: 15867243
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS, Georgiadis MS, Schuler BS, Pizzella P, Llorens V, Kasturi V, Steinberg SM, O'Neil K, Takimoto CH, Johnson BE.
    Clin Cancer Res; 2000 Jul 01; 6(7):2670-6. PubMed ID: 10914708
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Paclitaxel and carboplatin: a phase I study in advanced non-small cell lung cancer.
    Paccagnella A, Favaretto A, Oniga F, Ossana L.
    Semin Oncol; 1996 Dec 01; 23(6 Suppl 16):76-9. PubMed ID: 9007128
    [Abstract] [Full Text] [Related]

  • 20. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C, Capdevila J, Paredes A, Farré N, Ciria JP, Membrive I, Basterrechea L, Gomez-Segura G, Barnadas A.
    Lung Cancer; 2007 Nov 01; 58(2):238-45. PubMed ID: 17658655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.